Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells

Phase 2UnknownNCT05208060

Inmunotek S.L.48 enrolled

Overview

A mechanistic clinical trial with the aim to evaluate whether MV130 can induce the expression of a particular immune response (trained immunity) in peripheral blood cells. Therefore, the investigators are not evaluating efficacy in any disease or medical condition but rather assessing the immunological effect in immunogenicity of MV130 in healthy volunteers.

Bacillus Calmette-Guérin (BCG) has been postulated as a strategy to prevent transmission and reduce the incidence of infectious diseases due to its ability to induce trained immunity. However, it is not recommended to vaccinate with live-attenuated vaccines, such as BCG, to certain vulnerable populations including immunocompromised patients. This issue can be overcome with inactivated preparations that mediate trained immunity such as MV130. The safety of MV130 in pilot studies in patients with immunodeficiency or solid organ recipients, has been highlighted in recent studies. Based on the principles of trained immunity, it has recently been suggested that this concept can be further exploited in a next generation of anti-infectious vaccines: Trained immunity-based vaccines (TIbV). Thus, these vaccines may confer a broad protection far beyond to the nominal antigens they contain.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

DOUBLE

Enrollment

Conditions

Immune Response

Interventions

MV130BIOLOGICAL

Treatment administered sublingually

PlaceboOTHER

Treatment administered sublingually

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects that have provided written informed consent. * Healthy males and females 18 to 65 years, both included, at the time of enrolment. * Subjects who are able to provide cooperation and comply with dosing regimen. * Women of childbearing age (from menarche) should submit a urine pregnancy test with a negative result at the time of enrolment in the trial. Exclusion Criteria: * Simultaneous participation in another clinical trial. * Females who are pregnant or breast-feeding, or potential pregnant or breast-feeding females. * Subjects who are allergic to any of the components included in MV130. * Subjects with any concomitant disease or treatment that, according to the investigator criteria, may affect the development of this study, such as immunodeficiencies, malignancies involving bone marrow or lymphoid systems, medical treatment affecting the immune system (including corticosteroids, immunosuppressants, biological agents,…), human immunodeficiency virus, severe allergies, diabetes, hypertension, psychological disorders, etc. * Subjects who have been vaccinated within 12 months before inclusion (flu or any other vaccine different from COVID-19 vaccine), or who have planned to be vaccinated during the clinical study (excluding the COVID-19 vaccine). * Subjects who have had an infection that included fever and/or diarrhoea within 3 months before inclusion. * Subjects under metformin treatment during the last month before inclusion in the clinical study or during the clinical trial\*. * Subjects under statins treatment during the last month before inclusion in the clinical trial or during\*. \*: these drugs interfere with metabolic pathways involved in trained immunity induction. * Subjects who are allergic to any of the components included in the flu vaccine.

Locations (1)

Hospital Clínico San Carlos

Madrid, Spain

RECRUITING

Outcomes

Primary Outcomes

Increase ex vivo in cytokine response

The primary outcome is the increase ex vivo in cytokine response (TNF-alfa, IL-6 and/or IL-1beta) in PBMCs upon secondary restimulation (MV130, lipopolysaccharide \[LPS\], inactivated Candida albicans, Resiquimod-R848, Poly I:C and/or phytohemagglutinin \[PHA\]) in MV130 vaccinated subjects compared to placebo group, at days 15, 45 and/or 70, with respect to baseline.

Time frame: 70 days

Secondary Outcomes

Epigenetic and metabolic changes in purified monocytes from PBMCs, in a subgroup of MV130 vaccinated (n=12) versus placebo (n=12), at day 45 with respect to baseline.

It includes specific miRNA associated to trained immunity (miR155, miR146 and/or miR21, etc.) and histone marks (H3K4me3 and/or H3K27me3, among others), as epigenetic rewiring markers. It also includes lactate production, glucose consumption and mitochondrial activity as metabolic changes.

Time frame: 70 days

Changes in percentages of immune populations in peripheral blood including T and B cells, NK cells and subsets of monocytes, in MV130 group compared to placebo at days 15, 45 and/or 70, with respect to baseline.

Time frame: 70 days

Change in MV130 non-specific response (T and B cells from PBMCs) in MV130 treated group compared to placebo.

It includes T cell proliferation (days 15, 45 and/or 70) by labelling T cells with carboxyfluorescein succinimidyl ester (CFSE) prior to restimulation with PHA, inactivated C. albicans and flu antigens. Also, change of cytokine production (such as IFN-gamma, IL-17 and/or IL-10) from T cells upon restimulation (LPS, inactivated Candida albicans, flu antigens and/or PHA) (days 15, 45 and/or 70 with respect to baseline). It also includes antibody production: cross-reactive serum IgG against viral components. Different viral proteins/peptides will be tested (days 45 and 70 with respect to baseline). Antibody responses against flu antigens (IgG and IgA in serum and IgA in saliva) will be evaluated (days 45 and 70 with respect to baseline).

Central Contacts

Miguel Casanovas Verges, MD, PhD

CONTACT

664277223 mcasanovas@inmunotek.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.